Date 17.8.2022 20:44
Contact photo
Message Body

Houston, TX - Apr 18, 2022
The study vaccines included in this first stage of the trial are manufactured by Moderna, Inc., based in Cambridge, Mass. The trial will be adapted to enroll more participants to evaluate additional vaccine platforms and variant vaccines from other manufacturers as needed to further inform public health decisions.

Participants will be monitored for symptoms and adverse events following vaccination and will be asked to return to the clinic during set times over the course of 12-14 months to provide blood samples. Investigators will evaluate the samples in the laboratory to measure and characterize immune responses to SARS-CoV-2 strains. Investigators aim to have initial findings available by August 2022 - AFTER ONLY FOUR MONTHS, released in the UK....

Is this the winter 'flu jab then, classed as a covid booster, with mRNA after only initial findings of four months testing in phase 2.
This bivalent vaccine has an important role to play in protecting people in the U.K. from Covid-19 as we enter the winter months.
https://www.cnbc.com/2022/08/15/uk-becomes-first-country-to-approve-modernas-dual-covid-19-vaccine.html
Moderna's latest vaccine, called Spikevax, targets both the original strain and the first Omicron variant (BA.1), which emerged last winter. It is known as a bivalent vaccine as it takes aim at two forms of COVID.??? But spikevax is not new...it's been 'adapted'..

Sent Monday, 15 August 2022 at 21:53:16 BST
Subject: Covid: UK first country to approve dual-strain vaccine - BBC News

https://www.bbc.co.uk/news/health-62548336